Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Stock Up 3.4 %

NASDAQ AEMD opened at $0.40 on Thursday. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $1.85. The firm has a market capitalization of $5.84 million, a price-to-earnings ratio of -0.26 and a beta of 1.80. The company has a fifty day moving average of $0.59 and a two-hundred day moving average of $0.50.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. Equities research analysts anticipate that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Trading of Aethlon Medical

Several institutional investors and hedge funds have recently made changes to their positions in AEMD. Renaissance Technologies LLC bought a new position in shares of Aethlon Medical in the fourth quarter worth about $25,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical in the 4th quarter valued at about $26,000. Sassicaia Capital Advisers LLC bought a new position in Aethlon Medical in the 4th quarter worth about $31,000. Virtu Financial LLC purchased a new position in shares of Aethlon Medical during the fourth quarter worth approximately $81,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $186,000. 1.99% of the stock is currently owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.